SI3294740T1 - Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo - Google Patents

Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo

Info

Publication number
SI3294740T1
SI3294740T1 SI201630473T SI201630473T SI3294740T1 SI 3294740 T1 SI3294740 T1 SI 3294740T1 SI 201630473 T SI201630473 T SI 201630473T SI 201630473 T SI201630473 T SI 201630473T SI 3294740 T1 SI3294740 T1 SI 3294740T1
Authority
SI
Slovenia
Prior art keywords
prophylaxis
derivatives
novel
treatment
virus infection
Prior art date
Application number
SI201630473T
Other languages
English (en)
Slovenian (sl)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3294740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3294740T1 publication Critical patent/SI3294740T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201630473T 2015-05-08 2016-05-04 Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo SI3294740T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
SI3294740T1 true SI3294740T1 (sl) 2019-12-31

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630473T SI3294740T1 (sl) 2015-05-08 2016-05-04 Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo

Country Status (32)

Country Link
US (3) US9708325B2 (OSRAM)
EP (1) EP3294740B1 (OSRAM)
JP (1) JP6738352B2 (OSRAM)
KR (1) KR102690131B1 (OSRAM)
CN (1) CN107580596B (OSRAM)
AR (1) AR104528A1 (OSRAM)
AU (3) AU2016260683B2 (OSRAM)
BR (1) BR112017023959B1 (OSRAM)
CA (1) CA2982704C (OSRAM)
CL (1) CL2017002745A1 (OSRAM)
CO (1) CO2017009994A2 (OSRAM)
CR (1) CR20170496A (OSRAM)
DK (1) DK3294740T3 (OSRAM)
ES (1) ES2753777T3 (OSRAM)
HR (1) HRP20191942T1 (OSRAM)
HU (1) HUE045906T2 (OSRAM)
IL (2) IL254947B (OSRAM)
LT (1) LT3294740T (OSRAM)
MX (2) MX393198B (OSRAM)
MY (1) MY182353A (OSRAM)
NZ (2) NZ775222A (OSRAM)
PE (1) PE20171620A1 (OSRAM)
PH (1) PH12017502009A1 (OSRAM)
PL (1) PL3294740T3 (OSRAM)
PT (1) PT3294740T (OSRAM)
RS (1) RS59435B1 (OSRAM)
RU (1) RU2745269C2 (OSRAM)
SG (1) SG10202108841YA (OSRAM)
SI (1) SI3294740T1 (OSRAM)
TW (2) TWI706954B (OSRAM)
UA (1) UA120450C2 (OSRAM)
WO (1) WO2016180695A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
IL284255B (en) 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
TWI720250B (zh) * 2016-09-13 2021-03-01 瑞士商赫孚孟拉羅股份公司 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための7位置換スルホンイミドイルプリノン化合物及び誘導体
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
WO2020168017A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP4031544B1 (en) 2019-09-20 2024-02-28 Syngenta Crop Protection AG Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7684316B2 (ja) * 2020-01-27 2025-05-27 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EA200702235A1 (ru) * 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CA2745295C (en) * 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2776439B1 (en) * 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
BR112015024411B1 (pt) 2013-03-29 2022-02-22 Janssen Sciences Ireland Uc Desaza-purinonas macrocíclicas para o tratamento de infeções virais e composição farmacêutica que os compreende
AU2015303558B2 (en) 2014-08-15 2018-07-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
IL284255B (en) * 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
IL280769B1 (en) 2023-03-01
KR20180003612A (ko) 2018-01-09
HK1247925A1 (zh) 2018-10-05
CA2982704A1 (en) 2016-11-17
TWI768467B (zh) 2022-06-21
US20200109144A1 (en) 2020-04-09
PT3294740T (pt) 2019-10-29
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
CR20170496A (es) 2017-12-05
WO2016180695A1 (en) 2016-11-17
MX2020010949A (es) 2022-06-16
AU2016260683A1 (en) 2017-10-12
CA2982704C (en) 2023-10-24
AU2020256348B2 (en) 2022-06-16
CL2017002745A1 (es) 2018-05-18
MX376761B (es) 2025-03-07
US9708325B2 (en) 2017-07-18
CN107580596B (zh) 2020-07-14
AU2020256348A1 (en) 2020-11-12
EP3294740A1 (en) 2018-03-21
SG10202108841YA (en) 2021-09-29
ES2753777T3 (es) 2020-04-14
KR102690131B1 (ko) 2024-07-31
CO2017009994A2 (es) 2018-02-20
PH12017502009A1 (en) 2018-03-26
HRP20191942T1 (hr) 2020-01-10
TW201716410A (zh) 2017-05-16
JP6738352B2 (ja) 2020-08-12
TWI706954B (zh) 2020-10-11
TW202108584A (zh) 2021-03-01
LT3294740T (lt) 2019-11-25
US20160326177A1 (en) 2016-11-10
PE20171620A1 (es) 2017-11-02
RU2745269C2 (ru) 2021-03-22
MY182353A (en) 2021-01-20
RU2017142577A3 (OSRAM) 2019-10-31
NZ775222A (en) 2024-09-27
IL280769A (en) 2021-04-29
IL280769B2 (en) 2023-07-01
UA120450C2 (uk) 2019-12-10
NZ735648A (en) 2023-06-30
IL254947B (en) 2021-02-28
BR112017023959A2 (pt) 2018-07-17
EP3294740B1 (en) 2019-09-04
AR104528A1 (es) 2017-07-26
PL3294740T3 (pl) 2020-03-31
US20170275286A1 (en) 2017-09-28
AU2016260683B2 (en) 2020-10-29
DK3294740T3 (da) 2019-11-04
US10399983B2 (en) 2019-09-03
RU2017142577A (ru) 2019-06-10
BR112017023959B1 (pt) 2023-05-02
AU2022204666A1 (en) 2022-07-21
US11242345B2 (en) 2022-02-08
HUE045906T2 (hu) 2020-01-28
JP2018515509A (ja) 2018-06-14
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
MX393198B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
IL280769A (en) New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449A0 (en) 6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
SG11201509463YA (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
SI3137078T1 (sl) Zdravljenje okužbe s hepatitis delta virusom
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection